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Abstract
Background—Caffeine has been shown to prevent ultraviolet radiation-induced carcinogenesis 
and to inhibit growth of melanoma cells in experimental studies.
Objectives—We evaluated the association between caffeine intake, coffee consumption, and 
melanoma risk among three large cohort studies.
Methods—The analysis used data from 163,886 women in the Nurses’ Health Study II (NHS II, 
1991–2009) and Nurses’ Health Study (NHS, 1980–2008) and 39,424 men in the Health 
Professionals Follow-up Study (HPFS, 1986–2008). We used Cox proportional hazards models to 
estimate the hazard ratios (HR) with 95% confidence intervals (CI) of melanoma associated with 
dietary intakes.
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Results—We documented 2,254 melanoma cases over 4 million person-years of follow-up. After 
adjustment for other risk factors, higher total caffeine intake was associated with a lower risk of 
melanoma (≥393 mg/d vs. <60 mg/d: HR=0.78, 95% CI=0.64–0.96, Ptrend=0.048). The 
association was more apparent in women (≥393 mg/d vs. <60 mg/d: HR=0.70, 95% CI=0.58–0.85, 
Ptrend=0.001) than in men (HR=0.94, 95% CI=0.75–1.18, Ptrend=0.81), and more apparent for 
melanomas occurred on the body sites with higher continuous sun exposure (head, neck and 
extremities) (≥393 mg/d vs. <60 mg/d: HR=0.71, 95% CI=0.59–0.86, Ptrend=0.001) than for 
melanomas occurred on the body sites with lower continuous sun exposure (trunk including 
shoulder, back, hip, abdomen and chest) (HR=0.90, 95% CI=0.70–1.16, Ptrend=0.60). This pattern 
of association was similar to that for caffeinated coffee consumption, whereas no association was 
found for decaffeinated coffee consumption and melanoma risk.
Conclusions—Increasing caffeine intake and caffeinated coffee consumption may be protective 
against cutaneous malignant melanomas.
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INTRODUCTION
Cutaneous malignant melanoma is a potentially lethal form of skin cancer, and its incidence 
has been increasing in the United States and worldwide1–3. Numerous studies have 
identified solar ultraviolet (UV) radiation as the predominant environment risk factor for the 
development of cutaneous melanoma4, and the number of UV-induced sunburns is a strong 
predictor of melanoma incidence5. Interestingly, caffeine, a stimulant that is rich in coffee, 
has been shown to inhibit UV-induced sunburn lesions in the epidermis of mice and thus 
may mimic the effect of a sunscreen6–8. Oral administration of caffeine also has been 
demonstrated to enhance UV-induced cell apoptosis thereby enhancing the elimination of 
damaged precancerous cells9–11. In addition, both in vitro and in vivo studies have 
demonstrated an inhibitory effect of caffeine on the growth of melanoma cells12–15. 
Therefore, there is a good biological rationale for a potential preventive role of caffeine in 
the development of cutaneous melanoma.
To date, epidemiologic evidence for the association of coffee consumption and risk of 
cutaneous melanoma has been ambiguous. Limited prior studies have yielded conflicting 
results. Some studies suggested an inverse association between coffee consumption and risk 
of melanoma16–19, while others showed no association20–23. The heterogeneous results may 
be due to differences in study design and range of coffee consumption and inconsistent 
control for potential confounders. Furthermore, the numbers of melanoma cases have been 
limited in most previous studies. These studies also did not distinguish caffeinated vs. 
decaffeinated coffee16–19,21–23.
It has been documented that the role of sunlight in causing melanoma differs according to 
anatomic site, which is supportive of the hypothesis that melanomas may arise through 
divergent etiological pathways24,25. However, potential variation in the relation between 
coffee consumption and risk of melanoma by anatomic site has been unknown. According to 
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the existing biological evidence that caffeine may prevent UV-induced skin cancer11, it is 
plausible that caffeine may have a stronger protective effect against cutaneous 
carcinogenesis on the body sites receiving higher continuous UV radiation versus that on the 
body sites receiving lower continuous UV radiation.
To address the hypothesis that caffeine intake and coffee consumption may be associated 
with a reduced risk of cutaneous malignant melanoma, we investigated these questions of 
interest by using data from three large cohorts of women and men, including the Nurses’ 
Health Study II (NHS II, 1991–2009), Nurses’ Health Study (NHS, 1980–2008), and Health 
Professionals Follow-up Study (HPFS, 1986–2008).
METHODS
Study Populations
The NHS II was established in 1989 when 116,430 registered female nurses aged 25–42 
years were enrolled using a mailed baseline questionnaire which inquired about medical 
history and lifestyle practices. The NHS was established in 1976 when 121,700 married, 
registered, female nurses between the ages of 30 and 55 and residing in the United States at 
the time of enrollment responded to a baseline questionnaire that included questions about 
their medical history and lifestyle risk factors. The HPFS was established in 1986 when 
51,529 US male health professionals aged 40 to 75 years completed a baseline questionnaire 
on lifestyle, diet, and newly diagnosed diseases. Biennial questionnaires were used to collect 
data on disease outcomes and health related factors in all three cohorts. We had investigated 
the association of caffeine intake, coffee consumption and melanoma risk using data from 
the NHS and HPFS20, which lacked a detailed investigation for body site information on 
melanoma and used different cutoffs on caffeine intake levels. Thus, we revisited these 
studies and performed a meta-analysis of all three studies. The institutional review boards of 
Partners Health Care System and Harvard School of Public Health approved this study. We 
consider the participants’ completion and return of the self-administered questionnaires as 
informed consent.
Assessment of Melanoma Cases
Participants reported new diagnoses of skin cancer biennially. Permission is obtained from 
participants to acquire their medical and pathological reports if melanoma is reported. The 
medical and pathological records were reviewed by physicians who were unaware of 
exposure status to retrieve information on tumor histology if available. Melanomas were 
initially classified as the following three subgroups according to tumor location: head/neck 
melanomas, extremity melanomas (upper extremities between shoulder and hand fingers and 
lower extremities between hip and feet) and trunk melanomas (shoulder, back, hip, 
abdomen, and chest), according to the existing literature that head/neck melanomas may 
arise through a different causal pathway when compared to trunk melanomas25, and 
extremity melanomas may have a risk factor profile intermediate between the profiles for 
head/neck melanomas and trunk melanomas24,26. Because the associations with caffeine 
intake for melanomas of head/neck and extremities were similar, we then collapsed these 
two subgroups as a single group. In-situ melanomas were defined as early-stage tumors 
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restricted to the epidermis, and invasive melanomas were defined as those had grown into 
the dermis or surrounding tissues based on the pathological reports. A detailed body site and 
histological description for incident melanomas in each study is shown in eTable 1.
Assessment of Dietary Exposure
The dietary assessment was repeated using a food-frequency questionnaire (FFQ) at least 4 
years during the follow-up. Specifically, dietary information was collected in 1991, 1995, 
1999, 2003 and 2007 in the NHS II, in 1980, 1984, 1986, 1990, 1994, 1998, 2002 and 2006 
in the NHS, and in 1986, 1990, 1994, 1998, 2002 and 2006 in the HPFS. On all FFQs, 
participants were asked how often on average (i.e., never to 6+ servings/d) during the 
previous year they had consumed caffeinated and decaffeinated coffee (“one cup”), tea 
(“one cup or glass”), carbonated beverages (“one glass, bottle, or can”), and other food 
items. Carbonated beverages included caffeinated and caffeine-free colas and carbonated 
soft drinks. We calculated the total caffeine intake by summing the caffeine content for a 
specific amount of each food during the previous year multiplied by a weight proportional to 
the frequency of its consumption. By using the food-composition database of the US 
Department of Agriculture, we estimated that the caffeine content was 137 mg per cup of 
caffeinated coffee, 47 mg per cup of caffeinated tea, 46 mg per bottle or can of caffeinated 
carbonated beverage, and 7 mg per serving of caffeine-containing chocolate. The validity 
and reproducibility of the FFQ has been detailed elsewhere27,28. Specifically, high 
correlations were found between FFQ and diet records for coffee and other caffeine-rich 
beverage intake (coffee: r=0.78; tea: r=0.93; and caffeinated carbonated beverages: 
r=0.84)27,28. In addition, information on other dietary intakes including total energy and 
alcohol was also collected using the FFQs.
Assessment of Covariates
In the biennial follow-up questionnaires, we inquired and updated information on 
anthropometric and lifestyle factors for chronic diseases, including body height and weight, 
cigarette smoking, and physical activity. Data on menopausal status, post-menopausal 
hormone use, and rotating night shifts were collected in women29. Data on the following 
phenotypic and sun exposure related factors were collected through the follow-up 
questionnaires: family history of melanoma in first-degree relatives (parents and siblings); 
natural hair color; number of moles on legs (NHS II) or arms (NHS and HPFS); skin 
reaction to sun exposure for 2 hours or more as a child/adolescent; number of severe or 
blistering sunburns; average time spent in direct sunlight since high school; and cumulative 
UV flux since baseline30,31.
Statistical Analysis
A total of 95,248 women in the NHS II, 74,666 women in the NHS, and 39,424 men in the 
HPFS who had completed a dietary questionnaire and had no history of any cancer at 
baseline were included in the present analysis. We used cumulatively updated intakes in 
analyses to create the best estimates of long-term intake. That is, at the beginning of every 2-
year follow-up cycle, each intake was calculated as the mean of all reported intakes up to 
that time32. Participants contributed to follow-up time from the return month of baseline 
questionnaire to the month of the first diagnosis of a skin cancer (melanoma, squamous cell 
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carcinoma, or basal cell carcinoma), month of death, loss to follow-up, or the end of follow-
up (June 2009 for NHS II, June 2008 for NHS, and January 2008 for HPFS), whichever 
came first. We used Cox proportional hazards models to estimate the age-adjusted and 
multivariate hazard ratios (HRs) with 95% confidence intervals (CIs) of incident melanoma 
associated with dietary intakes. Multivariate analyses for caffeine intake were conducted 
with adjustment for known melanoma risk factors and potential lifestyle confounders which 
have been associated with skin cancer risk in previous studies29,30,33–35. Missing data during 
any follow-up period were coded as a missing indicator category for categorical variables 
(e.g., smoking status) and with carried-forward values for continuous variables (e.g., body 
mass index). Trend tests across categories of dietary intake were performed by assigning 
median values for these categories and treating the variables as continuous terms in the 
models. Results from different study cohorts were pooled using a random-effect model. P 
values for heterogeneity between studies were calculated with the use of the Q statistic. We 
used SAS software version 9.2 (SAS Institute Inc., Cary, North Carolina) for all statistical 
analyses. All statistical tests were 2-tailed, and the significance level was set at P<0.05.
RESULTS
We documented a total of 1,483 incident melanomas among women over 3,302,700 person-
years of follow-up (NHS II: 642 cases/1,543,932 person-years; NHS: 841 cases/1,758,768 
person-years) and 771 incident melanomas among men over 663,991 person-years of 
follow-up. Among women, 199 (13.4%) melanomas occurred on head and neck, 793 
(53.5%) on extremities, and 457 (30.8%) on trunk. Among men, 233 (30.2%) melanomas 
occurred on head and neck, 169 (21.9%) on extremities, and 307 (39.8%) on trunk (eTable 
1). To control for the heterogeneity in caffeine intake ranges across the study cohorts, we 
used the caffeine intake quintiles in the NHS II to regroup NHS and HPFS participants. 
Table 1 shows the characteristics of study participants by quintiles of caffeine intake in the 
NHS II. Participants with higher caffeine intake had higher consumption levels of 
caffeinated coffee, caffeinated tea, and caffeinated carbonated beverages; and were more 
likely to smoke, drink alcohol, and work in night shifts.
We found significant inverse association between increased caffeine intake and risk of 
overall melanoma in both NHS II and NHS cohorts (Table 2). After adjustment for other 
risk factors, the pooled multivariate HRs for overall melanoma from the lowest to highest 
category of caffeine intake in women were 1.00 (reference), 0.84 (95% CI, 0.70 to 1.01), 
0.90 (95% CI, 0.75 to 1.07), 0.80 (95% CI, 0.67 to 0.96), and 0.70 (95% CI, 0.58 to 0.85) 
(Ptrend=0.001). However, the association was not apparent in men (Ptrend=0.81). Pooled 
analysis for all three cohorts also suggested a significant inverse association between 
caffeine intake and risk of overall melanoma (multivariate HR=0.78 comparing the extreme 
categories of ≥393 mg/d vs. <60 mg/d, 95% CI, 0.64 to 0.96, Ptrend=0.048).
Interestingly, the inverse association appeared to be more apparent for melanomas occurred 
on head/neck and extremities than for melanomas occurred on trunk in all three cohorts. The 
inverse association for head/neck melanoma was similar with that for extremity melanoma 
(eTable 2), and the pooled multivariate HRs for melanoma on head, neck and extremities 
comparing the extreme categories were 0.66 (95% CI, 0.53 to 0.83, Ptrend=0.001) in women 
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and 0.71 (95% CI, 0.59 to 0.86, Ptrend=0.001) in both women and men (Table 3). In contrast, 
the association trend was not evident for trunk melanoma over the intake categories in the 
pooled analyses (all pooled Ptrend>0.20).
Caffeinated coffee consumption was also inversely associated with risk of overall melanoma 
in women, whereas decaffeinated coffee consumption showed no association with risk of 
overall melanoma in women (Table 4). Compared to women who abstained from caffeinated 
coffee, the pooled multivariate HRs for overall melanoma were 0.86 (95% CI, 0.72 to 1.02) 
for women who consumed less than 1 cup/d, 0.83 (95% CI, 0.70 to 0.98) for 1 to 2 cup/d, 
and 0.76 (95% CI, 0.64 to 0.89) for more than 2 cup/d (Ptrend=0.001). There was no 
apparent association for caffeinated coffee consumption and risk of overall melanoma in 
men (Ptrend=0.55). However, caffeinated coffee consumption appeared to be more strongly 
associated with melanoma on head, neck and extremities in all three cohorts (Table 5), and 
the pooled multivariate HRs comparing the extreme consumption levels (>2 cup/d vs. never) 
were 0.70 (95% CI, 0.58 to 0.85, Ptrend<0.001) in women and 0.74 (95% CI, 0.63 to 0.88, 
Ptrend<0.001) in both women and men. The inverse association for head/neck melanoma was 
also similar with that for extremity melanoma (eTable 3). In contrast, there was no evident 
association trend for caffeinated coffee consumption and risk of trunk melanoma over the 
consumption categories (all pooled Ptrend>0.60, Table 5). There was no apparent association 
between decaffeinated coffee consumption and melanoma on either head/neck/extremities or 
trunk (data not shown).
Associations of caffeine intake and caffeinated coffee consumption with in-situ and invasive 
melanomas were generally similar (eTable 4 and eTable 5). We conducted stratified 
analyses to evaluate whether the association between caffeine intake and risk of melanoma 
varied according to potential confounders, such as smoking status, alcohol use, and rotating 
night shifts in women. Results of subgroup analyses suggested associations generally similar 
to those from the main analyses, and there was no significant interaction between caffeine 
intake and these potential confounders (all Pinteraction>0.10, data not shown).
DISCUSSION
Based on data from three large prospective cohorts, we found that higher caffeine intake and 
caffeinated coffee consumption was associated with a lower risk of cutaneous malignant 
melanoma. In contrast, no association was found between consumption of decaffeinated 
coffee and risk of melanoma. Participants in the highest caffeine intake category (≥393 
mg/d) had a 22% lower risk of melanoma compared to those in the lowest intake category 
(<60 mg/d). The inverse association with caffeine intake and caffeinated coffee consumption 
was more apparent in women than in men, and more apparent for melanomas occurred on 
head, neck and extremities than for melanomas occurred on trunk . In contrast, no inverse 
association was found for melanoma on trunk with caffeinated coffee consumption. These 
findings are consistent with the existing literature from animal studies that caffeine may 
eliminate sunburn cells by enhancing UV-induced apoptosis and thereby prevent UV-
induced carcinogenesis6–10,36,37.
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Caffeine may inhibit UV-induced carcinogenesis through several biological mechanisms. 
Animal studies indicate that caffeine has a sunscreen effect that inhibits UV-induced 
formation of thymine dimers and sunburn lesions in the epidermis of mice7,11. Caffeine 
administration enhances UV-induced apoptosis by p53-dependent and p53-independent 
mechanisms. Pretreatment with oral caffeine enhanced UV-induced increases in p53 positive 
cells, p21 positive cells, and apoptotic sunburn cells9. Oral administration of coffee had a 
similar stimulatory effect on UV-induced apoptosis10. However, oral administration of 
caffeine had no effect on p53, p21, or apoptosis in the absence of UV irradiation, indicating 
that caffeine enhanced apoptosis only in DNA damaged epidermis but not in normal 
epidermis11. Previous experimental studies in tumor cells have found that caffeine can arrest 
cell cycle at the G2 checkpoint and preferentially radiosensitize tumor cells38,39, and that the 
radiosensitizing effects of caffeine are related to inhibition of the protein kinase activities of 
ataxia telangiectasia mutated and Rad3-related (ATR)40. A more recent study further 
demonstrated that administration of caffeine could enhance the removal of DNA-damaged 
cells by inhibiting the ATR-mediated phosphorylation of checkpoint kinase 1 and 
prematurely increasing the number of cyclin B1-containing cells that undergo lethal mitosis, 
and thereby inhibit UV-induced carcinogenesis37. In addition, UV-mediated NF-κB 
activation has been shown to result in acquired resistance to apoptosis and promotes the 
development of skin cancer41,42, whereas caffeine can inhibit UV-mediated NF-κB 
activation in melanoma cells43. Notably, caffeine also has been demonstrated to inhibit the 
growth of melanoma cells in vitro and in vivo12–15. An early study found that caffeine 
caused murine melanoma cells treated with cisplatin to differentiate, and this inhibited 
growth12. Further studies found that treatment with caffeine not only can inhibit tumor 
growth, prevent neovascularization, increase apoptosis of melanoma cells13, but also can 
inhibit metastatic behavior of melanoma cells14,15. Therefore, there exists a convincing 
biological plausibility that caffeine intake may play an important role in the prevention of 
cutaneous melanoma.
The findings of the present study are different from that in our previous analysis20. Several 
reasons may help explain the previous null results. First, the ranges of caffeine intake 
differed between the study cohorts, causing the heterogeneity in the HRs of higher intake 
groups vs. reference groups over study populations. Specifically, the ranges of the first 
quintiles were 0–59 mg/d in the NHS II, 0–132 mg/d in the NHS, and 0–42 mg/d in the 
HPFS. Table 2 shows the results using NHS II intake quintiles for all 3 cohorts, and the HR 
of the second category 60–140 mg/d vs. the first category 0–59 (<60) mg/d was 0.83 (0.60–
1.15) in the NHS. Therefore, when we use the 0–132 mg/d range (equals to <60 mg/d plus 
60–140 mg/d approximately) as the reference group for NHS, it will diminish the relative 
risk difference over intake categories and results in null HR estimates. To control for the 
heterogeneity in intake ranges over studies, we therefore used the same intake cutoffs for 
different study cohorts. Second, we treated melanoma as a single outcome in the previous 
analysis but did not account for the body site categories (head/neck/extremities vs. trunk) of 
the tumors. In the present study, we performed a more detailed, hypothesis-driven subtype 
analysis for melanoma, and found that the inverse association between caffeine intake, 
caffeinated coffee consumption and risk of melanoma was mainly attributable to melanomas 
occurred on head, neck and extremities with higher continuous sun exposure but not 
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melanomas occurred on trunk with lower continuous sun exposure. Third, we also expanded 
the follow-up period to start from 1980 (instead of 1984 in the previous analysis) in the NHS 
when the first FFQ was used to collect diet information in the NHS participants32, and thus 
increased the statistical power. Melanoma was first asked in 1982 in the NHS, and we 
sought to validate self-reported melanoma diagnoses during 1980–1982 by medical and 
pathological records.
The association between caffeine intake, caffeinated coffee consumption and melanoma risk 
was not apparent among men in the HPFS, though the inverse association was also more 
apparent for melanoma on head, neck and extremities than for melanoma on trunk. This may 
be due to a modest statistical power for men, and a lower proportion of melanoma on head, 
neck and extremities and a higher proportion of melanoma on trunk in men than in women 
(eTable 1). It is evident that sun exposure patterns differ between women and men. Men 
generally receive less continuous solar UV radiation on extremities as compared to women 
because of different dressing styles, thereby resulting in different proportions of extremity 
melanoma over genders (21.9% in men vs. 53.5% in women). Therefore, it is possible that 
caffeine’s protective effect against melanoma among men may not be as apparent as among 
women when overall melanoma is treated as a single outcome. Similarly, a previous study 
from Norway also documented a significant inverse association between coffee consumption 
and melanoma risk in women but not in men18. The Norwegian study included 25,049 
women and 25,708 men, among whom a total of 108 malignant melanomas were 
documented18. However, this study did not differentiate between caffeinated coffee and 
decaffeinated coffee and also did not account for the variation in the association by tumor 
site.
The strengths of this study include its prospective design, large sample size, long-term 
follow-up, detailed melanoma case ascertainment with clear separation for different 
subtypes, repeated assessments of dietary and lifestyle factors, and the ability to differentiate 
between caffeinated coffee and decaffeinated coffee. Our study also has several limitations. 
The cohorts studied mostly comprised white, well-educated health professionals, which 
potentially limits the generalizability of the findings. However, restricting the sample to 
health professionals also reduces potential residual confounding from socioeconomic status. 
In the present study, caffeine intake was also positively associated with several lifestyle 
factors including alcohol intake, smoking status and rotating night shifts. However, we did 
not detect appreciable interaction between caffeine intake, coffee consumption and these 
potential confounders, suggesting that residual confounding by these variables should not be 
a substantial concern.
In sum, we found that caffeine intake and caffeinated coffee consumption were inversely 
associated with risk of cutaneous malignant melanoma based on data from three large 
cohorts. The association was more apparent in women than in men, and was also more 
apparent for melanomas occurred on head, neck and extremities than for melanomas 
occurred on trunk. We did not find any association between decaffeinated coffee 
consumption and melanoma risk. These findings are consistent with previous biological 
evidence that caffeine may prevent UV-induced carcinogenesis, and support the hypothesis 
that melanoma on different body sites may arise through divergent causal pathways24–26. 
Wu et al. Page 8
Epidemiology. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Given the highly prevalent coffee consumption and sun exposure behaviors in the general 
population and the rising melanoma incidence over the decades worldwide1–3, our findings 
may help convey important public health implication, and may be potentially useful for the 
prevention of sun-induced malignant melanomas.
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